Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article compares the immunology of cancer and the placenta and suggests that immunotherapy for pregnant cancer patients could be feasible with careful exploration, though no new clinical results are reported.

This study suggests that CD8+ cytotoxic T lymphocytes play a crucial role in the development of alopecia areata, based on observations in rodent models that mimic human autoimmune disease.

In this case study, a 65-year-old male with hepatocellular carcinoma treated with the PD-1 inhibitor Sintilimab developed alopecia universalis alongside significant tumor regression and complete remission, highlighting a rare immune-related adverse event with effective anti-tumor outcomes.

This review discusses the range of cutaneous immune-related adverse events induced by immune checkpoint inhibitors and the proposed mechanisms underlying these skin reactions, but reports no new clinical results.

This letter to the editor discusses immune checkpoint inhibitor-related alopecia and insights into its pathophysiology using non-invasive diagnostic techniques, but reports no new clinical results.

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

In this study, the researchers synthesized copper-doped mesoporous silica nanoparticles and observed that they enhance tumor microenvironment regulation and, when paired with disulfiram, effectively kill cancer cells while also showing synergistic anti-tumor effects with immune checkpoint inhibitors.

This study found that tumor immunotherapy, while effective against solid tumors, can disrupt the immune balance in hair follicles, causing follicular toxicity and alopecia, highlighting the need for targeted interventions to manage these adverse effects.

This study analyzed FAERS data to explore the risk and onset patterns of autoimmune skin diseases associated with immune checkpoint inhibitors, finding a strong association particularly with bullous pemphigoid and emphasizing the need for vigilant monitoring of these adverse effects.

This study found that FRβ knockout mice exhibited autoimmune symptoms and slower tumor growth compared to wild type mice, suggesting that the FRβ receptor may play a role in regulating immune responses in tumors and autoimmune conditions.

The authors discussed that SOCS1 and SOCS3's inhibition of JAKs plays a significant role in the development of JAK inhibitor drugs for skin inflammatory diseases and malignancies.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

This review describes how cutaneous toxicity from kinase inhibitors, immune checkpoint inhibitors, and chemotherapeutics could potentially serve as a biomarker for anticancer treatment efficacy, but highlights the need for more extensive research to confirm this association.

This case report describes a rare instance of alopecia areata linked to nivolumab treatment in a patient with hepatocellular carcinoma.

This article reviews the cutaneous side effects of immune checkpoint inhibitors and targeted therapies for skin cancers, noting that while generally mild, these effects can influence treatment decisions and quality of life, underscoring the need for physicians to be aware of these adverse reactions.

This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.

In this study, 37.5% of patients with nodal or metastatic cutaneous melanoma treated with immune checkpoint inhibitors developed skin adverse events, primarily low-grade rashes, vitiligo, and other dermatological symptoms, occurring mainly after 10 weeks of treatment.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

This review discusses the challenges and opportunities in targeting the hedgehog pathway for aggressive cancers, emphasizing the complexities of treatment resistance, immune response, and the potential of combining immune checkpoint inhibitors with hedgehog pathway inhibitors, but reports no new clinical results.

In this study, researchers identified six novel prognostic biomarkers for bladder cancer and developed a predictive model that effectively stratifies patients into high-risk and low-risk groups based on immune cell infiltration differences and gene expression.

This study observed that pantethine, a vitamin B5 precursor, attenuates tumor growth in immunocompetent mice by enhancing antitumor immunity, but its effect is limited by immune cell exhaustion over time.

This review highlights the promising potential of using nanomedicine-based immunotherapy in tissue regeneration, detailing recent advances in nanocomposite biomaterials and the modulation of immune responses to create optimal environments for tissue repair.

HPV infection is linked to better survival in advanced anal cancer, higher radiation doses improve survival, especially in HPV-negative patients, and prostaglandin E₂ pretreatment can protect mouse hair follicles from radiation damage.

This bibliometric analysis examines the research landscape of T cells in atherosclerosis and identifies key trends and emerging research areas, highlighting the field's stabilization over the past decade.

This review discusses recent advances in understanding Merkel cell carcinoma biology, including the development of genetically-engineered mouse models and potential therapeutic targets, but reports no new clinical results.

This study provides a framework for understanding different types of alopecias based on immune privilege collapse at specific follicular sites, revealing distinct patterns in immune effector programs and stromal influences depending on the alopecia type.

This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.

This study constructed a comprehensive atlas of prenatal human skin, revealing that innate immune cells, such as macrophages, play a crucial role in skin morphogenesis by interacting with non-immune cells, influencing hair follicle formation and angiogenesis beyond their traditional immune functions.